Search the Newsreel

Insider Selling: Cue Biopharma (NASDAQ:CUE) CEO Sells 18,258 Shares

Cue Biopharma CEO Shao-Lee Lin sold 18,258 shares of the company's stock for over $522,000 to cover tax withholding obligations from vested equity awards. This sale reduced her ownership by 2.52%, following a previous sale of 40,000 shares for $1.08 million. The company recently …

Insider plans 58,258-share stock sale (NASDAQ: CUE) under Rule 144

An insider of Cue Biopharma (NASDAQ: CUE) has filed a Rule 144 notice to sell up to 58,258 shares of common stock. These shares originated from restricted stock units that vested on August 1, 2026. The sale is planned to occur in two tranches …

Senti Biosciences Holdings Inc. (SNTI) Stock Price | Live Quotes & Charts | NASDAQ

Bright Minds Biosciences (NASDAQ:DRUG) Issues Quarterly Earnings Results

Bright Minds Biosciences (NASDAQ:DRUG) reported quarterly earnings per share of ($0.17), significantly surpassing analysts' consensus estimate of ($1.28). Following the announcement, shares fell 2.0% to $76.44. Analysts maintain a generally positive outlook on the stock, with an average "Buy" rating and a consensus price …

Moleculin Biotech Releases Q2 2026 Financial Results

Moleculin Biotech (MBRX) reported a net loss of $7.6 million for Q2 2026, with a significant improvement in loss per share, narrowing to $1.40 from $12.25 in Q2 2025. The company, focused on therapeutic candidates for tumors and viruses, generated no revenue but continued …

Cue Biopharma (NASDAQ:CUE) Posts Quarterly Earnings Results, Misses Estimates By $22.45 EPS

Is Castle Biosciences Inc (CSTL) a Bargain After 3.0% Drop? GF Value Says Undervalued

Castle Biosciences Inc (CSTL) shares recently dropped 3.0%, leading to a 7.5% decrease over the past week, but GuruFocus' GF Value indicates the stock is slightly undervalued. Despite a strong GF Score of 81/100, driven by high growth potential, the company faces significant challenges …

Discipline and Rules-Based Execution in BCRX Response

This article provides an AI-driven analysis for Biocryst Pharmaceuticals Inc. (BCRX), highlighting strong sentiment, a mid-channel oscillation pattern, and an exceptional risk-reward setup targeting a 15.0% gain. It details three distinct institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis for …

Wuxi Biologics (Cayman) Stock Sheds 1.3% in Hong Kong

Perceptive Advisors (NASDAQ: SLDB) details 11.2% beneficial stake and warrant limits

Perceptive Advisors LLC and related entities, including Joseph Edelman, have reported a beneficial ownership of 12,046,579 shares in Solid Biosciences Inc. (NASDAQ: SLDB), representing an 11.2% stake. This includes common stock and pre-funded warrants, with the latter subject to a 9.99% beneficial ownership limitation …

TuHURA Biosciences (NASDAQ:HURA) Posts Earnings Results, Beats Estimates By $0.01 EPS

Valion Bio (VBIO) investor group reports 1.74M shares, capped at 9.9% stake

An investor group comprising 3i, LP, Tumim Stone Capital, LLC, 3i Management LLC, and Maier J. Tarlow has filed an amended Schedule 13D for Valion Bio, Inc. (VBIO), reporting beneficial ownership of 1,742,699 common shares, representing a 9.9% stake. This percentage is calculated based …

Athira Pharma (NASDAQ:LONA) Announces Quarterly Earnings Results

Athira Pharma (NASDAQ:LONA) reported quarterly earnings of ($0.80) per share, significantly beating the consensus estimate of ($1.90). Following the announcement, shares rose 1.4% to $7.98. Analysts maintain a "Moderate Buy" rating with a $16 price target, and institutional investors hold 57.12% of the company's …

CSTL (CSTL) files notice to sell 24,908 common shares on NASDAQ

A holder of CSTL common stock has filed a notice of intent to sell up to 24,908 shares on NASDAQ through Morgan Stanley Smith Barney LLC Executive Financial Services. The indicated aggregate market value of these shares is $741,493.72, and they originated from restricted …

BioNTech SE (NASDAQ:BNTX) Just Reported And Analysts Have Been Cutting Their Estimates

BioNTech SE (NASDAQ:BNTX) recently reported disappointing quarterly results, with statutory earnings falling short and revenues missing forecasts by 32%. Analysts have since cut next year's revenue estimates and increased loss per share forecasts, reflecting a significant change in sentiment. Despite the revised outlook, the …

Is Biohaven’s Narrowing Losses and AI Board Hire Altering The Investment Case For Biohaven (BHVN)?

Biohaven Ltd. reported narrowing losses in Q2 2026, with a net loss of US$137.31 million, and appointed AI-focused investor John Yetimoglu to its Board. Despite these developments, the company still faces significant financial risk due to zero revenue, heavy ongoing losses, and a short …

Dino Rossi Sells 25,000 Shares of Krystal Biotech (NASDAQ:KRYS) Stock

Can AbCellera Biologics (ABCL)’s Vertex Pharmaceuticals Incorporated (VRTX) Deal Turn its TCE Platform Into a Breakthrough?

On July 29, AbCellera Biologics Inc. (NASDAQ:ABCL) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced a strategic collaboration to research, develop, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases. Under the agreement, AbCellera will leverage its proprietary TCE platform to lead discovery, while Vertex will …

Gujarat Themis Biosyn Publishes Q1 FY27 Earnings Call Transcript

BioXcel Therapeutics (BTAI) files Form 3 for new director Susan E. Atkins

BioXcel Therapeutics, Inc. (BTAI) has filed a Form 3 to report the initial beneficial ownership for its new director, Susan E. Atkins. This filing indicates her position as a director but does not list any equity transactions or current holdings. The document also notes …

BioXcel Therapeutics (BTAI) director receives option grant for 17,000 shares

BioXcel Therapeutics director Susan E. Atkins was granted stock options for 17,000 shares of common stock on August 12, 2026, with an exercise price of $1.06 per share and an expiration date of August 12, 2036. The options will vest over three years, with …

Assembly Biosciences (ASMB) Stock Jumps As Losses Shrink And Revenue Builds

Assembly Biosciences (ASMB) stock jumped 10% after reporting significantly reduced losses and increased revenue. The company's net loss from continuing operations narrowed from US$40.177 million to US$6.383 million, and total revenue rose to US$71.097 million. Despite these improvements and an expanded Phase I pipeline, …

Is Biohaven (BHVN)’s Latest Regeneron Pharmaceuticals (REGN) Deal a Major Catalyst for its Pipeline?

Two prominent biopharmaceutical names, Biohaven Ltd. (NYSE:BHVN) and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), are deepening their relationship across oncology. On July 20, Biohaven announced a clinical supply agreement with Regeneron to evaluate the combination of BHV-1530 and Regeneron's cemiplimab (Libtayo) in patients with solid tumors. …

Helix BioPharma Reshapes Board to Align with Oncology Growth Strategy

MCDONALDS CORP (MCD) president Anderson Skye details options, PRSUs and stock

Valion Bio (OTC: VBIO) faces going concern risk and Nasdaq bid price warning

Valion Bio, Inc. (OTC: VBIO) has reported significant financial concerns, including a net loss of $13.3 million for the first six months of 2026 and an accumulated deficit of $66.5 million, raising substantial doubt about its ability to continue as a going concern. The …

BioNexus Gene Lab Corp (BGLC) grants CEO 338,709 fully vested shares

BioNexus Gene Lab Corp (BGLC) announced that its CEO and director, Tan Lee Su-Leng, received a fully vested stock award of 338,709 common shares. These shares, granted under the company's 2025 Equity Incentive Plan for completed services, were valued at $1.55 per share based …

BioNexus Gene Lab Corp (BGLC) director receives 32,258-share equity award

BioNexus Gene Lab Corp director Bin Abdul Hamid Muhammad Azrul received a fully vested equity award of 32,258 common shares on August 13, 2026. The award, valued at $1.55 per share, was granted under the company’s 2025 Equity Incentive Plan for completed services, with …

BioNexus Gene Lab Corp (BGLC) director granted 16,129-share fully vested stock award

BioNexus Gene Lab Corp (BGLC) director Low Jook Yuen received a fully vested stock award of 16,129 shares of common stock on August 13, 2026, for services rendered. This equity compensation, granted under the company's 2025 Equity Incentive Plan, had no cash consideration and …

Valion Bio, Inc. Q2 2026: Net loss $7.1M, EPS $(2.17) — 10-Q Summary

Valion Bio, Inc. reported a significant widening of its net loss in Q2 2026 to $7.1M, up from $1.93M in Q2 2025, with diluted loss per share at $(2.17). The company recorded no revenue from continuing operations. Despite financial losses, Valion Bio highlighted progress …

Twist Bioscience Corp (TWST) Stock Down 5.4% but Still Overvalued -- GF Score: 69/100

Twist Bioscience Corp (TWST) shares dropped by 5.4% to $118.57, yet the stock is considered 126.4% overvalued compared to its GF Value™ of $52.38. Despite a strong growth rank of 10/10, the company's profitability and valuation ranks are low, coupled with significant insider selling …

What's Going On With Cannara Biotech Inc. Stock Friday?

Valion Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Satellos Bioscience Sets Up US$50 Million U.S. At-the-Market Share Sales Facility

Belite Bio (BLTE) Could Be 21% Below Fair Value As FDA Priority Review Lands

Belite Bio (BLTE) is currently undervalued by 21% according to Simply Wall St. following the FDA's acceptance of its New Drug Application for tinlarebant with Priority Review. Despite a recent one-day dip, the stock has shown strong momentum over the last month and year, …

Perceptive Advisors group reports 9.1% Nautilus (NAUT) ownership in updated 13D/A

Perceptive Advisors and its related entities have filed an updated 13D/A, disclosing a 9.1% beneficial ownership in Nautilus Biotechnology, Inc. (NAUT), totaling 11,634,211 shares. This ownership is primarily held by Perceptive Life Sciences Master Fund, Ltd. and C2 Life Sciences LLC, with Perceptive Advisors …